

1 *Brief Report*

2 **Phosphatidylethanolamines are the main lipid class altered in red blood cells**  
3 **from patients with VPS13A disease/chorea-acanthocytosis**

4 Kevin Peikert, MD<sup>1,2,3</sup>, Adrian Spranger<sup>1</sup>, Gabriel Miltenberger-Miltenyi, MD<sup>4</sup>, Hannes Glaß,  
5 PhD<sup>1</sup>, Björn Falkenburger, MD<sup>5,6</sup>, Christian Klose, PhD<sup>7</sup>, Donatienne Tyteca, PhD<sup>8</sup>, Andreas  
6 Hermann, MD PhD<sup>1,2,3,9</sup>

7 <sup>1</sup>Translational Neurodegeneration Section "Albrecht Kossel", Department of Neurology, University Medical Center Rostock,  
8 University of Rostock, Germany

9 <sup>2</sup> Center for Transdisciplinary Neurosciences Rostock (CTNR), University Medical Center Rostock, Rostock, Germany

10 <sup>3</sup> United Neuroscience Campus Lund-Rostock (UNC), Rostock site

11 <sup>4</sup> Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Portugal

12 <sup>5</sup> Department of Neurology, Technische Universität Dresden, Dresden, Germany

13 <sup>6</sup> Deutsches Zentrum für Neurodegenerative Erkrankungen, Dresden, Germany

14 <sup>7</sup> Lipotype GmbH, Dresden, Germany

15 <sup>8</sup> CELL Unit, de Duve Institute, UCLouvain, Brussels, Belgium

16 <sup>9</sup> Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) Rostock/Greifswald, Rostock, Germany

17

18 **Corresponding Author:**

19 Prof. Andreas Hermann, MD, PhD; Translational Neurodegeneration Section "Albrecht  
20 Kossel"; Department of Neurology; University Medical Center Rostock; Gehlsheimer Straße  
21 20, 18147 Rostock, Germany; Phone: +49(0)381 494-9511; e-Mail:  
22 Andreas.Hermann@med.uni-rostock.de

23

24 **Running Title:** Lipidomics in VPS13A disease

25 **Word count (up to 1700 words, abstract 150):** 1707, 151

26 **Figures/tables (up to 2):** 2

27 **References (up to 40):** 26

28 **Financial Disclosure/Conflict of Interests:** CK is CTO and shareholder of Lipotype GmbH,  
29 other than that none related to the manuscript.

30 **Funding Sources:** This study was funded by the MeDDrive grant (TU Dresden). K.P. is  
31 supported by Rostock Academy of Science (RAS). A.H. is supported by the Hermann und Lilly  
32 Schilling-Stiftung für medizinische Forschung im Stifterverband.

33

34

35

36

37

38 **Abstract**

39 **Background:** VPS13A disease (chorea-acanthocytosis) is an ultra-rare disorder caused by loss  
40 of function mutations in *VPS13A* characterized by striatal degeneration and by red blood cell  
41 (RBC) acanthocytosis. VPS13A is a bridge-like protein mediating bulk lipid transfer at  
42 membrane contact sites.

43 **Objectives:** To assess the lipid composition of patient-derived RBCs.

44 **Methods:** RBCs collected from 5 VPS13A disease patients and 12 control subjects were  
45 analyzed by mass spectrometry (lipidomics).

46 **Results:** While we found no significant differences on the overall lipid class level, alterations  
47 in certain species were detected: phosphatidylethanolamine species with both longer chain  
48 length and higher unsaturation were increased in VPS13A disease samples. Specific  
49 ceramide, phosphatidylcholine and sphingomyelin species were also altered.

50 **Conclusions:** The presented alterations of particular lipid species in RBCs in VPS13A disease  
51 contribute to 1) the understanding of acanthocyte formation and 2) future biomarker  
52 identification. Lipid distribution seems to play a key role in the pathophysiology of VPS13A  
53 disease.

54

55

56

57

58

59

60

61

62

63

64

## 65 Introduction

66 VPS13A disease (formerly known as chorea-acanthocytosis) is a neurodegenerative disorder  
67 of the young adulthood and an important differential of Huntington's disease<sup>1</sup>. Together  
68 with XK disease (McLeod syndrome) it has been classified as neuroacanthocytosis syndrome  
69 as it is characterized by striatal degeneration and the presence of deformed red blood cells  
70 (RBCs), referred to as acanthocytes<sup>2</sup>. Typical clinical manifestations include a variety of  
71 movement disorders (chorea and dystonia with orofacial predominance, in later stages  
72 parkinsonism), epilepsy, behavioral and cognitive impairment as well as peripheral neuro-  
73 and myopathy<sup>1</sup>.

74 The autosomal-recessive condition is caused by biallelic pathogenic variants in the *VPS13A*  
75 gene leading in most cases to a complete loss of the respective protein, VPS13A/chorein<sup>3</sup>.  
76 VPS13A belongs to a family of 4 proteins, VPS13A-D, that are all related to  
77 neurodegenerative or neurodevelopmental disorders, such as hereditary parkinsonism  
78 (VPS13C) or ataxia (VPS13D)<sup>4-6</sup>. Only recently, VPS13A has been assigned to the new protein  
79 superfamily of bridge-like lipid transfer proteins (BLTPs)<sup>7,8</sup>. Forming hydrophobic grooves  
80 that span between two organellar membranes at membrane contact sites, these proteins  
81 mediate direct bulk lipid transfer, most likely selective for phospholipids<sup>9</sup>. VPS13A localizes  
82 between the endoplasmic reticulum and mitochondria, lipid droplets or the plasma  
83 membrane<sup>9</sup>. At the plasma membrane, it has been shown to form a complex with the  
84 putative scramblase XK<sup>10,11</sup>. In support of a pathomechanistic role of altered membrane lipid  
85 distribution and supply in VPS13A disease, elevated levels of several sphingo- and  
86 phospholipids have been recently found in the striatum of VPS13 patients<sup>12</sup>. Also, in  
87 Huntington's disease, a distinct shift in the sphingolipid profile of the caudate has been  
88 reported<sup>13</sup>.

89 In this exploratory study, we aimed to study the lipid composition of RBCs from VPS13A  
90 patients for various reasons: 1) RBCs are – besides neurons – prominently affected by the  
91 disease as a high proportion are acanthocytic. 2) RBCs are “products” of a complex  
92 rearrangement of membranes and organelles during erythropoiesis<sup>14</sup> potentially requiring  
93 membrane lipid transfer. 3) RBCs are – in contrast to brain tissue – easily obtainable. RBC  
94 lipid composition may therefore be an ideal biomarker candidate.

95

96

## 97 **Methods**

98 Five genetically confirmed VPS13 patients (4 males, 1 female, mean age 45.6, min 32, max 52  
99 years) and 12 healthy controls (9 males, 3 females, mean age 40.7, min 23, max 56 years)  
100 were included in this study. Demographic and clinical data of patients are shown in Table S1.  
101 The study was approved by the ethics committee at the Technische Universität Dresden  
102 (EK45022009, EK78022015). All participants gave written informed consent in accordance  
103 with the Declaration of Helsinki.

104 EDTA blood samples were processed in accordance to the sample preparation guidelines  
105 from Lipotype GmbH (Dresden, Germany; see supplementary material). Mass spectrometry-  
106 based lipid analysis was performed by Lipotype GmbH as previously described using a  
107 QExactive Orbitrap mass spectrometer (Thermo Fisher Scientific, Darmstadt, Germany)<sup>15</sup>.  
108 Table S2 shows the list of analyzed lipid classes and the respective structural detail level of  
109 the analysis.

110 Lipid data was analyzed in mol% for better comparability. An occupational threshold was  
111 applied to filter lipid (sub)species that were not adequately measured to solidify findings  
112 (see supplementary material).

113 Multiple t-tests on all remaining (sub)species were performed (without assuming a  
114 consistent standard deviation). In order to account for multiple testing, the Benjamini  
115 Hochberg procedure with a false discovery rate of 5% was used. Analysis was performed at  
116 different levels: lipid class level, lipid (sub)species level, structural or functional category  
117 level as well as grouped by chain length/double bounds number/OH-groups number. For  
118 visualization of the results on the lipid (sub)species level, a Vulcano plot was generated.

119

## 120 **Results**

121 There was no statistically significant difference in age and sex distribution between the two  
122 groups analyzed in this study (Table S3).

123 Untargeted lipidomic analysis was achieved by mass spectrometry by screening for 23 lipid  
124 classes. In total, 575 lipid species and subspecies were measured. After application of the  
125 occupational threshold, 313 lipid species and subspecies remained for further analysis. Out  
126 of the 23 classes, 13 were easily detectable including ceramide (Cer), cholesterol (Chol),  
127 hexosylceramide (HexCer), lyso-phosphatidylcholine (LPC), phosphatidylcholine (PC),  
128 phosphatidylethanolamine (PE), phosphatidylcholine-ether (PE O-), phosphatidylinositol (PI),  
129 phosphatidylserine (PS) and sphingomyelin (SM), in agreement with previous reports on  
130 RBCs <sup>16</sup>. Moreover, we were able to detect additional species such as lyso-  
131 phosphatidylethanolamine (LPE), phosphatidate (PA) and phosphatidylcholine-ether (PC O-).

132 On the lipid class level, no relevant differences between healthy controls and VPS13A  
133 patients could be detected (Fig 1A). The most distinct difference was seen in the PI class with  
134 less mol% in the disease group, however, this did not reach statistical significance ( $p=0.07$ ,  
135  $q=0.51$ ). Also, after grouping the lipids into structural (glycerophospholipids, sphingolipids,  
136 and sterols) or functional categories (lyso vs. membrane lipids), analysis did not reveal  
137 striking differences (Fig 1 B, C), as was the case for the number of double bounds and  
138 hydroxyl groups of the lipids (Fig 1 D, E). Likewise, while there was a tendency of decrease of  
139 lipids with medium length fatty acid chains (30-36 C-atoms) and of increase of lipids with  
140 very long chains (39-44 C-atoms) in the patient group compared to control, none of these  
141 differences reached statistical significance (Fig 1 F).

142 On the lipid species and subspecies level, however, distinct differences with small effect size  
143 (fold change) were observed. The increase of Cer34:1;2 was the most significant finding (Fig  
144 2 A, B). Most of the (sub)species with significant change after Benjamini Hochberg procedure  
145 belonged to the PE or PE O- classes. Within the PEs, a shift in the fatty chain lengths became  
146 obvious: PE subspecies with longer fatty acid chains tended to be increased, species with  
147 shorter chains to be decreased (Fig. 2 C). This is in line with the (nonsignificant) shift that has  
148 been observed in the overall chain length analysis (Fig. 1 F). In addition, decrease of single PC  
149 and SM species were also detected.

150

## 151 Discussion

152 VPS13A disease has recently become paradigmatic for a new pathophysiological concept in  
153 neurodegeneration: disturbed bulk lipid transfer at membrane contact sites<sup>2,9,17</sup>. VPS13A is a  
154 bridge-like protein enabling direct bulk lipid transfer between intracellular membranes. It  
155 seems that disturbances of this process are central for VPS13A and related diseases although  
156 the exact role of bulk lipid transfer in neuronal and other mainly affected cells such as RBCs  
157 is subject of further research.

158 Based on these recent molecular developments in the field, we studied for the first time the  
159 lipid composition of RBCs from VPS13A patients using state-of-the-art lipidomics analysis.  
160 RBCs are clearly affected by the disease as acanthocytosis is a core feature and VPS13A  
161 deficient RBCs reflect at least partly the pathophysiology of the disease<sup>1,18-20</sup>. Therefore,  
162 RBCs may be an easily accessible surrogate and biomarker for pathology of the nervous  
163 system. Of note, there is significant evidence that lipid dysmetabolism is causal for the  
164 development of acanthocytosis. First, hypo-/abetalipoproteinemia leads to the appearance  
165 of acanthocytes<sup>21,22</sup>. Second, in liver failure where acanthocytosis is observed, irregularities  
166 in lipid metabolism, particularly an excess of chol, have been associated with the  
167 deformation of RBCs<sup>23</sup>. On the other side, lipid analysis in the “pre-lipidomics era” has not  
168 revealed consistent differences in RBCs from neuroacanthocytosis patients<sup>18</sup>.

169 In line with that, our study did not show a generalized major disturbance of lipid classes, but  
170 revealed interesting distinct changes at the lipid species and subspecies level, including PE  
171 (O-) and Cer, but also single PC, and SM (sub)species.

172 PE play a central role in autophagosome formation and is a regulator of autophagy<sup>24</sup>, a  
173 process which has been shown to be impaired in VPS13A disease, as reflected by the  
174 presence of membrane remnants<sup>19,20</sup>, and which is essential during erythropoiesis.  
175 Moreover, the relative abundance of PE species highly evolves during reticulocyte  
176 maturation into RBCs: longer and more unsaturated PE species decrease whereas smaller  
177 and more saturated PE species increase (Minetti et al, BioRxiv,  
178 <https://doi.org/10.1101/2023.06.02.543386>). Interestingly, we showed here a reverse “acyl  
179 chain remodeling”: The former group increased in VPS13A patients while the latter  
180 decreased, suggesting impairment of RBC maturation. Therefore, these findings may be  
181 related to acanthocyte formation during erythropoiesis and the pathophysiology of VPS13A  
182 disease. Supporting this possibility, Cer, PC and PE species were also shown to be affected in

183 hypobetalipoproteinemia, another acanthocyte-related disease<sup>22</sup>. Interestingly, Csf1, a  
184 Vps13-like BLTP, has been shown to transfer PEs to the ER for GPI anchor synthesis<sup>25</sup>.

185 Also, as PE is a non-bilayer forming lipid, especially with longer chain length<sup>26</sup>, an increase of  
186 longer PE species might at least partially explain the morphological alterations of  
187 acanthocytes. Moreover, non-bilayer lipids may affect integration of proteins into  
188 membranes, their lateral movement and their function<sup>27</sup>.

189 Cer act as the foundational element for complex sphingolipids and is important in cellular  
190 signaling. Accordingly, abnormal Cer levels have been associated with several  
191 neurodegenerative conditions<sup>28</sup>.

192 The rather distinct lipid alterations may be viewed as unexpected considering the function of  
193 VPS13A as lipid transfer protein. However, as most of the altered lipids are phospholipids,  
194 this finding is consistent with the suspected role of VPS13A as (specifically) phospholipid  
195 transferring protein<sup>9</sup>. Also, quantitative analyses might not have captured localized changes  
196 in membrane composition without major disturbances of overall lipid content. Furthermore,  
197 variations within the RBC population (e.g., acanthocytic vs. non-acanthocytic) could have  
198 masked specific alterations in a subgroup of cells. As VPS13A plays a role in lipid transfer  
199 between organellar membranes and as mature RBCs lack such organelles, the pathogenic  
200 process occurs potentially mainly during erythropoiesis. Therefore, quantitative lipid analysis  
201 might reveal more pronounced alterations in RBC precursor cells. Another limitation of this  
202 study relates to the low number of patient samples due to the ultra-rarity of the disease  
203 which might have resulted in an insufficient statistical power to detect even more subtle  
204 changes.

205 The RBC lipidomics data presented are not conclusive with the data derived from post  
206 mortem brain tissue<sup>12</sup>. This is partially due to the differences in covered lipid classes by the  
207 measurements. However, this may also point to different effects of VPS13A deficiency in  
208 RBCs and the brain.

209 In summary, the alterations of particular lipid species in RBCs in VPS13A disease contributes  
210 to the pathophysiological understanding. Further studies need to focus on lipid composition  
211 of RBC precursor cells and on potential localized changes in distinct RBC membrane domains.

212 Also, our results may result in the development of PE species as biologically relevant  
213 biomarker for VPS13A disease which is a prerequisite for future clinical studies<sup>29</sup>.

214

## 215 **Acknowledgments**

216 We thank the patients and control subjects for participating in this study. We are grateful to Glenn  
217 (†) and Ginger Irvine as the founders of the Advocacy for Neuroacanthocytosis Patients  
218 ([www.naadvocacy.org](http://www.naadvocacy.org)) and to Susan Wagner and Joy Willard-Williford as representatives of the NA  
219 Advocacy USA ([www.naadvocacyusa.org](http://www.naadvocacyusa.org)). We thank the advocacies for their support and research  
220 funding. We also thank Dr. Jenny Leopold (Institute for Medical Physics and Biophysics, Faculty of  
221 Medicine, Leipzig University, Germany) for her expert advice.

222 K.P. is supported by the Rostock Academy of Science (RAS), A.H. by the “Hermann und Lilly Schilling-  
223 Stiftung für medizinische Forschung im Stifterverband”. D.T. is Senior Research Associate of Belgian  
224 F.R.S.-FNRS.

225

## 226 **Authors' Roles**

227 KP, HG, AH – study design. KP and AH: patient recruitment, KP, AS, HG – execution. KP, AS, GMM, BF,  
228 CK, DT – data analysis. KP, AH: funding acquisition. AH: supervision, project administration; KP, AS,  
229 GMM, DT – writing. All authors - editing of final version of the manuscript.

230

## 231 **Financial Disclosures of all authors (for the preceding 12 months)**

232 KP: Received funding from the Rostock Academy of Science (RAS) and the Deutschen Gesellschaft für  
233 Parkinson und Bewegungsstörungen e.V. Stock Ownership in medically-related fields.

234 AH has received personal fees and non-financial support from ITF Pharma, Biogen and Desitin during  
235 the conduct of the study outside of the submitted work. He received funding from the Schilling  
236 Stiftung für medizinische Forschung im Stifterverband, VDI/BMBF, ESF, target ALS foundation outside  
237 the submitted work.

238 CK is CTO and shareholder of Lipotype GmbH.

239 AS, GMM, HG, BF, DT have no financial disclosure to declare.

240



241

242


243

244

245

246 **Figures**

247 **Figure 1**




248

249 **Fig 1** Lipidomics analysis on lipid class (A), structural category (B), functional category (C) level.  
 250 Structural analysis of lipids in respect to number of double bounds (D), fatty acid chain length (E), and  
 251 number of hydroxyl groups (F).

252 *Ctrl* controls, *VPS13A* VPS13A patients, *Cer* Ceramide, *Chol* Cholesterol, *HexCer* Hexosylceramide, *LPC*  
 253 lyso-Phosphatidylcholine, *LPE* lyso-Phosphatidylethanolamine, *PA* Phosphatidate, *PC* (O-  
 254 Phosphatidylcholine (-ether), *PE* (O-) Phosphatidylethanolamine (-ether), *PI* Phosphatidylinositol, *PS*  
 255 Phosphatidylserine, *SM* Sphingomyelin, *GPL* glycerophospholipids, *SL* sphingolipids, *ST* sterols, *LYS*  
 256 lyso lipids, *MEM* membrane lipids.

257 **Figure 2**



258

259 **Fig 2** Lipidomics analysis on species and subspecies level. Volcano blot showing all analysed  
 260 (sub)species (A). The horizontal dotted line represents the threshold of statistical significance after  
 261 Benjamini Hochberg procedure with a false discovery rate of 5%. (B) shows all significantly different  
 262 (sub)species between healthy control and VPS13A disease groups. (C) Relative change of  
 263 Phosphatidylethanolamine (PE) subspecies in VPS13A disease sorted by fatty acid chain length and  
 264 double bond number; results are expressed as percentage of controls (healthy control values were  
 265 set 100%).

266 *Ctrl* controls, *VPS13A* VPS13A patients, *Cer* Ceramide, *Chol* Cholesterol, *HexCer* Hexosylceramide, *LPC*  
 267 lyso-Phosphatidylcholine, *LPE* lyso-Phosphatidylethanolamine, *PA* Phosphatidate, *PC* (O-  
 268 Phosphatidylcholine (-ether), *PE* (O-) Phosphatidylethanolamine (-ether), *PI* Phosphatidylinositol, *PS*  
 269 Phosphatidylserine, *SM* Sphingomyelin

270  
271  
272  
273  
274  
275  
276  
277

## 278 **References**

- 279 1. Peikert K, Dobson-Stone C, Rampoldi L, et al. VPS13A Disease. *GeneReviews*<sup>®</sup> [Internet].  
280 University of Washington, Seattle; 1993; 2002 [updated 2023].
- 281 2. Walker RH, Peikert K, Jung HH, Hermann A, Danek A. Neuroacanthocytosis Syndromes: The  
282 Clinical Perspective. *Contact (Thousand Oaks)*. 2023;6:25152564231210339.  
283 doi:10.1177/25152564231210339
- 284 3. Dobson-Stone C, Velayos-Baeza A, Filippone LA, et al. Chorein detection for the diagnosis of  
285 chorea-acanthocytosis. *Ann Neurol*. Aug 2004;56(2):299-302. doi:10.1002/ana.20200
- 286 4. Velayos-Baeza A, Vettori A, Copley RR, Dobson-Stone C, Monaco AP. Analysis of the human  
287 VPS13 gene family. *Genomics*. Sep 2004;84(3):536-49. doi:10.1016/j.ygeno.2004.04.012
- 288 5. Lesage S, Drouet V, Majounie E, et al. Loss of VPS13C Function in Autosomal-Recessive  
289 Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy.  
290 *Am J Hum Genet*. Mar 3 2016;98(3):500-513. doi:10.1016/j.ajhg.2016.01.014
- 291 6. Seong E, Insolera R, Dulovic M, et al. Mutations in VPS13D lead to a new recessive ataxia with  
292 spasticity and mitochondrial defects. *Ann Neurol*. Jun 2018;83(6):1075-1088. doi:10.1002/ana.25220
- 293 7. Braschi B, Bruford EA, Cavanagh AT, Neuman SD, Bashirullah A. The bridge-like lipid transfer  
294 protein (BLTP) gene group: introducing new nomenclature based on structural homology indicating  
295 shared function. *Hum Genomics*. Dec 02 2022;16(1):66. doi:10.1186/s40246-022-00439-3

- 296 8. Kumar N, Leonzino M, Hancock-Cerutti W, et al. VPS13A and VPS13C are lipid transport  
297 proteins differentially localized at ER contact sites. *J Cell Biol.* Oct 1 2018;217(10):3625-3639.  
298 doi:10.1083/jcb.201807019
- 299 9. Hanna M, Guillén-Samander A, De Camilli P. RBG Motif Bridge-Like Lipid Transport Proteins:  
300 Structure, Functions, and Open Questions. *Annu Rev Cell Dev Biol.* Jul 05 2023;doi:10.1146/annurev-  
301 cellbio-120420-014634
- 302 10. Park JS, Neiman AM. XK is a partner for VPS13A: a molecular link between Chorea-  
303 Acanthocytosis and McLeod Syndrome. *Mol Biol Cell.* 10 2020;31(22):2425-2436.  
304 doi:10.1091/mbc.E19-08-0439-T
- 305 11. Guillén-Samander A, Wu Y, Pineda SS, et al. A partnership between the lipid scramblase XK  
306 and the lipid transfer protein VPS13A at the plasma membrane. *Proc Natl Acad Sci U S A.* Aug 30  
307 2022;119(35):e2205425119. doi:10.1073/pnas.2205425119
- 308 12. Miltenberger-Miltenyi G, Jones A, Tetlow AM, et al. Sphingolipid and Phospholipid Levels Are  
309 Altered in Human Brain in Chorea-Acanthocytosis. *Mov Disord.* Aug 2023;38(8):1535-1541.  
310 doi:10.1002/mds.29445
- 311 13. Phillips GR, Saville JT, Hancock SE, et al. The long and the short of Huntington's disease: how  
312 the sphingolipid profile is shifted in the caudate of advanced clinical cases. *Brain Commun.*  
313 2022;4(1):fcab303. doi:10.1093/braincomms/fcab303
- 314 14. Moras M, Lefevre SD, Ostuni MA. From Erythroblasts to Mature Red Blood Cells: Organelle  
315 Clearance in Mammals. *Frontiers in physiology.* 2017;8:1076. doi:10.3389/fphys.2017.01076
- 316 15. Sampaio JL, Gerl MJ, Klose C, et al. Membrane lipidome of an epithelial cell line. *Proc Natl*  
317 *Acad Sci U S A.* Feb 01 2011;108(5):1903-7. doi:10.1073/pnas.1019267108
- 318 16. Leidl K, Liebisch G, Richter D, Schmitz G. Mass spectrometric analysis of lipid species of  
319 human circulating blood cells. *Biochim Biophys Acta.* Oct 2008;1781(10):655-64.  
320 doi:10.1016/j.bbailip.2008.07.008

- 321 17. Peikert K, Danek A. VPS13 Forum Proceedings: XK, XK-Related and VPS13 Proteins in  
322 Membrane Lipid Dynamics. *Contact*2023.
- 323 18. Adjobo-Hermans MJ, Cluitmans JC, Bosman GJ. Neuroacanthocytosis: Observations, Theories  
324 and Perspectives on the Origin and Significance of Acanthocytes. *Tremor Other Hyperkinet Mov (N Y)*.  
325 2015;5:328. doi:10.7916/D8VH5N2M
- 326 19. Lupo F, Tibaldi E, Matte A, et al. A new molecular link between defective autophagy and  
327 erythroid abnormalities in chorea-acanthocytosis. *Blood*. Dec 22 2016;128(25):2976-2987.  
328 doi:10.1182/blood-2016-07-727321
- 329 20. Peikert K, Federti E, Matte A, et al. Therapeutic targeting of Lyn kinase to treat chorea-  
330 acanthocytosis. *Acta Neuropathol Commun*. May 2021;9(1):81. doi:10.1186/s40478-021-01181-y
- 331 21. Levy E. Insights from human congenital disorders of intestinal lipid metabolism. *J Lipid Res*.  
332 May 2015;56(5):945-62. doi:10.1194/jlr.R052415
- 333 22. Cloos AS, Daenen LGM, Maja M, et al. Impaired Cytoskeletal and Membrane Biophysical  
334 Properties of Acanthocytes in Hypobetalipoproteinemia - A Case Study. *Frontiers in physiology*.  
335 2021;12:638027. doi:10.3389/fphys.2021.638027
- 336 23. Sharma R, Holman CJ, Brown KE. A thorny matter: Spur cell anemia. *Ann Hepatol*.  
337 2023;28(1):100771. doi:10.1016/j.aohep.2022.100771
- 338 24. Hsu P, Shi Y. Regulation of autophagy by mitochondrial phospholipids in health and diseases.  
339 *Biochim Biophys Acta Mol Cell Biol Lipids*. Jan 2017;1862(1):114-129.  
340 doi:10.1016/j.bbalip.2016.08.003
- 341 25. Toulmay A, Whittle FB, Yang J, et al. Vps13-like proteins provide phosphatidylethanolamine  
342 for GPI anchor synthesis in the ER. *J Cell Biol*. Mar 07 2022;221(3)doi:10.1083/jcb.202111095
- 343 26. de Kruijff B. Lipid polymorphism and biomembrane function. *Curr Opin Chem Biol*. Dec  
344 1997;1(4):564-9. doi:10.1016/s1367-5931(97)80053-1

345 27. van den Brink-van der Laan E, Killian JA, de Kruijff B. Nonbilayer lipids affect peripheral and  
346 integral membrane proteins via changes in the lateral pressure profile. *Biochim Biophys Acta*. Nov 03  
347 2004;1666(1-2):275-88. doi:10.1016/j.bbamem.2004.06.010

348 28. Clausmeyer L, Fröhlich F. Mechanisms of Nonvesicular Ceramide Transport. *Contact*  
349 (*Thousand Oaks*). 2023;6:25152564231208250. doi:10.1177/25152564231208250

350 29. Peikert K, Glaß H, Federti E, et al. Targeting Lyn Kinase in Chorea-Acanthocytosis: A  
351 Translational Treatment Approach in a Rare Disease. *J Pers Med*. May 10  
352 2021;11(5)doi:10.3390/jpm11050392

353